Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGT251
- Development stage
- Preclinical
- Lead developer
- Syndeio Biosciences
- Modality
- Small Molecules
01
Overview
AGT251 is a novel small molecule, specifically a tocopherol-omega alkanol chain derivative, identified for its protective effects against muscle atrophy. It functions as an antioxidant and modulates the Notch signaling pathway by counteracting its induction under cytotoxic stress. This leads to a decrease in the expression of Notch1 and Notch3, and subsequently represses the Notch target gene Hes1 and the atrophy/remodeling gene MuRF1. Preclinical studies in murine models of cancer-associated cachexia and amyotrophic lateral sclerosis (ALS) have shown that AGT251 ameliorates body and muscle weight loss, reduces muscular atrophy markers, and improves survival.
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)
Beyond the preview
Go deeper on AGT251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGT251.